Annexin Q3 2023: Our Comment - Redeye

Redeye returns with an update following Annexin’s Q3 report. We note that it has been an eventful quarter for the company, including progress with its RVO and Cancer tracks. The report came in as expected but we expect the company to present a financing solution relatively soon.

Länk till analysen i sin helhet: https://www.redeye.se/research/947962/annexin-q3-2023-our-comment?utm_source=finwire&utm_medium=RSS